14:19:31 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-01 Kvartalsrapport 2024-Q2
2024-05-02 Kvartalsrapport 2024-Q1
2024-03-14 Ordinarie utdelning GMAB 0.00 DKK
2024-03-13 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-08-03 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-03-30 Ordinarie utdelning GMAB 0.00 DKK
2023-03-29 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-30 Ordinarie utdelning GMAB 0.00 DKK
2022-03-29 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-05-05 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning GMAB 0.00 DKK
2021-04-13 Årsstämma 2021
2021-02-23 Bokslutskommuniké 2020
2020-11-04 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-06 Kvartalsrapport 2020-Q1
2020-03-27 Ordinarie utdelning GMAB 0.00 DKK
2020-03-26 Årsstämma 2020
2020-02-19 Bokslutskommuniké 2019
2019-04-01 Ordinarie utdelning GMAB 0.00 DKK
2019-03-29 Årsstämma 2019
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-04-11 Ordinarie utdelning GMAB 0.00 DKK
2018-04-10 Årsstämma 2018
2018-02-21 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-29 Ordinarie utdelning GMAB 0.00 DKK
2017-03-28 Årsstämma 2017
2017-02-22 Bokslutskommuniké 2016
2016-11-10 Kapitalmarknadsdag 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-09 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-03-18 Ordinarie utdelning GMAB 0.00 DKK
2016-03-17 Årsstämma 2016
2016-02-17 Bokslutskommuniké 2015
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-11 Kvartalsrapport 2015-Q2
2015-05-12 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning GMAB 0.00 DKK
2015-03-26 Årsstämma 2015
2015-03-02 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-04-10 Ordinarie utdelning GMAB 0.00 DKK
2014-04-09 Årsstämma 2014
2014-03-04 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-18 Ordinarie utdelning GMAB 0.00 DKK
2013-04-17 Årsstämma 2013
2013-03-07 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-15 Kvartalsrapport 2012-Q2
2012-05-09 Kvartalsrapport 2012-Q1
2012-04-26 Ordinarie utdelning GMAB 0.00 DKK
2012-04-25 Årsstämma 2012
2011-11-02 Kvartalsrapport 2011-Q3
2011-08-03 Kvartalsrapport 2011-Q2
2011-05-11 Kvartalsrapport 2011-Q1
2011-04-07 Ordinarie utdelning GMAB 0.00 DKK
2011-04-06 Årsstämma 2011
2011-02-28 Bokslutskommuniké 2010
2010-04-22 Ordinarie utdelning GMAB 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Genmab är ett läkemedelsbolag. Bolaget är specialiserade inom forskning och utveckling av antikroppar, som huvudsakligen används vid behandling av cancerpatienter med lymfatisk leukemi och solida tumörer. Forskning och utveckling utgår ifrån bolagets egenutvecklade tekniska plattform och verksamhet innehas på global nivå. Genmab grundades 1999 och har sitt huvudkontor i Köpenhamn.
2020-11-04 17:04:37

November 4, 2020; Copenhagen, Denmark;
Interim Report for the First Nine Months Ended September 30, 2020

Highlights

  • Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosis
  • Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple myeloma
  • Janssen was granted U.S. FDA approval for DARZALEX® (daratumumab) in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma based on Phase 3 CANDOR study
  • DARZALEX net sales increased 35% compared to the first nine months of 2019 to USD 2,937 million, resulting in royalty income of DKK 2,898 million for the first nine months of 2020
  • Genmab commenced binding arbitration of two matters under daratumumab license agreement with Janssen

      ·Announcement of plan to transition Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S.

“Genmab continued to deliver on the promise of improving the lives of patients, with multiple regulatory milestones for Genmab-created products under development by our partners, including the exciting U.S. FDA’s approval of Kesimpta and the 8th U.S. FDA approval for DARZALEX,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “During the first nine months of 2020, with our solid financial footing Genmab has continued its focused investment in advancing its proprietary antibody product pipeline and building its capabilities as we evolve into a fully integrated biotech.”

Financial Performance First Nine Months of 2020

  • Revenue was DKK 8,067 million in the first nine months of 2020 compared to DKK 2,405 million in the first nine months of 2019. The increase of DKK 5,662 million, or 235%, was primarily driven by the upfront payment from AbbVie pursuant to our new collaboration announced in June and higher DARZALEX royalties.
  • Net sales of DARZALEX by Janssen Biotech Inc. (Janssen) were USD 2,937 million in the first nine months of 2020 compared to USD 2,168 million in the first nine months of 2019, an increase of USD 769 million, or 35%.
  • Operating expenses were DKK 2,641 million in the first nine months of 2020 compared to DKK 1,943 million in the first nine months of 2019. The increase of DKK 698 million, or 36%, was driven by the advancement of epcoritamab (DuoBody®-CD3xCD20) and DuoBody-PD-L1x4-1BB, additional investments in our product pipeline, and the increase in new employees to support the expansion of our product pipeline.
  • Operating income was DKK 5,426 million in the first nine months of 2020 compared to DKK 462 million in the first nine months of 2019. The increase of DKK 4,964 million was driven by higher revenue, which was partly offset by increased operating expenses.

Outlook
Genmab is maintaining its 2020 financial guidance published on August 20, 2020.

Conference Call
Genmab will hold a conference call in English to discuss the results for the first nine months of 2020 today, Wednesday, November 4, at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST. To join the call dial
+1 646 741 3167 (U.S. participants) or +44 2071 928338 (international participants) and provide conference code 7839599.


A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investors.

Contact:
Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com 

The Interim Report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra®, Kesimpta® and Sensoready® are trademarks of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO™ are trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc.

Download the full Interim Report for the First Nine Months of 2020 on attachment or at www.genmab.com/investors.

CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark